InsidersTradesSigma
Follow the Airsculpt Technologies, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Airsculpt Technologies, Inc. has published 81 public disclosures. Market capitalisation: €342.9m. The latest transaction was disclosed on 14 May 2026 (Attribution). Among the most active insiders: Chernett Jorey. The full history is openly available.
81
Insider Decl.
n/a
Thresholds
€4m
21 ops.
Buy Volume
€25m
4 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Airsculpt Technologies, Inc. Hold (neutral), based on 1 analysts. Average price target: US$4.50.
34Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,254 of 29,063 companies
33.3
score / 100
Value30
Quality37
FCF yld0.4%
Earn yld-6.2%
EV/EBITDA·
ROE-12%
Gross mgn59%
Net mgn-7.7%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 14 May 2026
Declarations81 total
100,286 shares0Common StockSEC:0001889114-26-000002:0
100,286 shares0Common StockSEC:0001705224-26-000002:0
100,286 shares0Common StockSEC:0001889258-26-000002:0
40,000 shares@ US$2.540.031% mcap66.2% of flowCommon StockSEC:0000921895-26-001030:0
Canonical exit: 16 Jul 2026 (T+90)
20,000 shares@ US$2.600.016% mcap33.8% of flowCommon StockSEC:0000921895-26-000989:0
Canonical exit: 13 Jul 2026 (T+90)
68,027 shares0Common Stock, $0.001 Par ValueSEC:0001104659-26-042161:0
238,095 shares0Common Stock, $0.001 Par ValueSEC:0001104659-26-042163:0
55,272 shares0Common Stock, $0.001 Par ValueSEC:0001584009-26-000002:0
60,000 shares@ US$2.9353.6% of flowCommon StockSEC:0000921895-26-000944:0
Canonical exit: 6 Jul 2026 (T+90)
90,000 shares@ US$2.8243.9% of flowCommon StockSEC:0000921895-26-000915:0
Canonical exit: 2 Jul 2026 (T+90)
50,000 shares@ US$2.9120.1% of flowCommon StockSEC:0000921895-26-000802:0
Canonical exit: 21 Jun 2026 (T+90)
40,000 shares@ US$2.7710.6% of flowCommon StockSEC:0001193805-26-000307:0
Canonical exit: 18 Jun 2026 (T+90)
38,379 shares@ US$2.7985.0% of flowCommon Stock, $0.001 Par ValueSEC:0001104659-26-032869:0
77,702 shares@ US$2.6419.9% of flowCommon StockSEC:0000921895-26-000752:0
Canonical exit: 17 Jun 2026 (T+90)
83,000 shares@ US$2.5617.0% of flowCommon StockSEC:0001193805-26-000283:0
Canonical exit: 15 Jun 2026 (T+90)
105,848 shares@ US$2.4317.2% of flowCommon StockSEC:0000921895-26-000696:0
Canonical exit: 14 Jun 2026 (T+90)
88,000 shares@ US$2.159.8% of flowCommon StockSEC:0000921895-26-000668:0
Canonical exit: 9 Jun 2026 (T+90)
45,600 shares@ US$2.004.7% of flowCommon StockSEC:0000921895-26-000638:0
Canonical exit: 4 Jun 2026 (T+90)
80,000 shares@ US$1.717.0% of flowCommon StockSEC:0000921895-26-000613:0
Canonical exit: 1 Jun 2026 (T+90)
24,217 shares@ US$2.5832.7% of flowCommon Stock, $0.001 Par ValueSEC:0001104659-26-011081:0
147,059 shares0Common Stock, $0.001 Par ValueSEC:0001104659-26-007005:0
56,097 sharesCommon Stock, $0.001 Par ValueSEC:0001104659-25-103868:0
462,957 shares@ US$4.007.5% of flowCommon Stock, $0.001 Par ValueSEC:0001104659-25-058584:0
Canonical exit: 7 Sept 2025 (T+90)
2,118 shares@ US$3.6020.1% of flowCommon Stock, $0.001 Par ValueSEC:0001104659-25-050994:0
Canonical exit: 17 Aug 2025 (T+90)
58,594 shares0Common StockSEC:0001104659-25-046310:0
25 of 81 declarations
关于 Airsculpt Technologies, Inc.
AirSculpt Technologies, Inc. 是一家在美国纳斯达克市场上市的公司，股票代码为AIRS。该公司在美学医疗领域运营，专注于高端身体塑形手术。公司的核心产品是一个微创治疗平台，旨在去除脂肪、紧致皮肤并重塑身体目标区域，并高度强调精确性、舒适性和恢复速度。在其监管和投资者材料中，AirSculpt 将自己描述为一家全国性的高端身体塑形手术提供商，仅通过其自有诊所提供服务，并由外科医生、护士和患者护理顾问提供支持。([investors.airsculpt.com](https://investors.airsculpt.com/static-files/0480fb6a-a699-41e0-888f-2e9fc33f246b)) AirSculpt 成立于2012年，总部位于美国佛罗里达州迈阿密海滩。其业务围绕 AirSculpt Technologies, Inc. 及其子公司构建，采用垂直控制模式，结合了专有医疗程序、标准化患者体验和品牌服务形式。公司的旗舰方法 AirSculpt® 被定位为一种获得专利的下一代身体塑形技术，具有微创性，无需针头、手术刀、缝线或全身麻醉。这种专有定位是其相对于更传统整形外科提供商的关键竞争优势。([investors.airsculpt.com](https://investors.airsculpt.com/static-files/0480fb6a-a699-41e0-888f-2e9fc33f246b)) 其主要服务包括广泛的脂肪去除和脂肪移植程序。AirSculpt 销售多种品牌治疗，包括 AirSculpt®、AirSculpt® +、AirSculpt® Smooth、Power BBL®、Up a Cup™ 和 Hip Flip™。AirSculpt® + 结合了脂肪去除和皮肤紧致，而 AirSculpt® Smooth 旨在减少脂肪团。这些产品表明，该公司不仅销售单一程序，还在构建一个专有美学解决方案组合，旨在满足身体塑形类别中不同患者的需求。([investors.airsculpt.com](https://investors.airsculpt.com/static-files/0480fb6a-a699-41e0-888f-2e9fc33f246b)) 从地理上看，该公司的业务足迹主要在美国，并在加拿大设有额外业务。最近的披露还显示了海外的战略收缩，包括2025年关闭其伦敦设施，这表明管理层正将资本和运营重心放在最具吸引力的市场上。2026年初，管理层还强调了更新的市场进入战略、改进的业务流程和新程序的推出，作为加速增长努力的一部分。([investors.airsculpt.com](https://investors.airsculpt.com/static-files/0480fb6a-a699-41e0-888f-2e9fc33f246b)) 最近的运营趋势表明该公司正处于转型模式。2025年，AirSculpt 完成了11,852例手术，报告收入为151.8 million美元，低于2024年。2026年4月，管理层报告同店销售额环比改善，并提供了2026年全年收入约为151 million至157 million美元，调整后EBITDA为15 million至17 million美元的指引。从投资角度看，AirSculpt 仍然是一个具有差异化品牌和专有程序的利基美学医疗运营商，但它也面临需求周期性和执行风险，因为它正在努力稳定增长并提高盈利能力。([investors.elitebodysculpture.com](https://investors.elitebodysculpture.com/node/8641/pdf))
